1 / 11

Neuroendocrine Tumors Market

Neuroendocrine tumors are a complex group of tumors that develop predominantly in the digestive or respiratory tracts, but can occur in many<br>areas of the body.

DelveInsight
Télécharger la présentation

Neuroendocrine Tumors Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Neuroendocrine Tumors (NET) Market Insights, Epidemiology, and Market Forecast- 2028

  2. NEUROENDOCRINE TUMORS (NET) NEUROENDOCRINE TUMORS CLASSIFICATION Neuroendocrine tumors are a complex group of tumors that develop predominantly in the digestive or respiratory tracts, but can occur in many areas of the body. NETs classified as: Gastroenteropancreatic neuroendocrine tumors, Pancreatic neuroendocrine tumors, Gastrointestinal neuroendocrine tumors, Carcinoid tumor, Functioning and, Non-functioning neuroendocrine tumors. SYMPTOMS ORIGIN NETs gradually tend to appear when the tumor grows or hormones are secreted by the tumor itself. Some of the NETs symptoms are discomfort or pain the in the rectum, heartburn or indigestion, bowel obstruction, stomach ulcers, and patches of red, itchy and painful skin. These tumors arise from cells called neuroendocrine cells. Like all cancers, NETs develop when the specialized cells undergo changes causing them to divide uncontrollably and grow into an abnormal tissue mass (tumor). • DelveInsight © 2019 | All rights reserved

  3. NEUROENDOCRINE TUMORS EPIDEMIOLOGY 01 02 03 05 04 Total Prevalence Prevalence in US Prevalence in Europe Cases Tumor Cases Neuroendocrine Tumors total prevalent population in 7 major markets (7MM)* was approximately 452,900 in 2017. It was estimated approximately 199,000 Neuroendocrine Tumors prevalent cases were there in the United States in 2017. Germany had the highest NET prevalent population with 49,600 cases while Spain had the lowest NETs prevalent population of 27,000 in 2017. The European 5 countries and the US accounted for 43% and 44% respectively of the NET total prevalent cases in the 7MM* in 2017. There were 35,000 patients having localized tumor, 13,000 patients having regional tumor and 18,000 cases with distant tumor in the United States in 2017. {*7MM includes - USA, EU-5 (Germany, Spain, Italy, France and UK), Japan} • DelveInsight © 2019 | All rights reserved

  4. NEUROENDOCRINE TUMORS MARKET Neuroendocrine tumors therapeutic market in seven major markets was USD 3,570.0 million in 2017. The United States accounts for the largest Neuroendocrine tumors market size, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan. Among the EU5 countries, Germany had the highest Neuroendocrine tumors market size with approximately USD 330.0 million in 2017. Spain had the lowest Neuroendocrine tumors market size with approximately USD 180.0 million in 2017. • DelveInsight © 2019 | All rights reserved

  5. NETs MARKET (%) DISTRIBUTION IN 2017 United States Japan United Kingdom Germany France Italy Spain 5.1% 51.7% 12.7% 9.3% 7.6% 6.9% 6.7% • DelveInsight © 2019 | All rights reserved

  6. NETs MARKET SIZE BY THERAPIES Drug- CRN01941 by Crinetics Pharmaceuticals Drug- RRx-001 By EpicentRx Drug- ATG-008 By Antengene Neuroendocrine Tumors market dynamics is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period of 2019-2028. The emerging therapies and companies involved in Neuroendocrine Tumors treatment are- Drug- Sulfatinib By Hutchison MediPharma Drug- Entrectinib By Ignyta • DelveInsight © 2019 | All rights reserved

  7. COMPLETE INFORMATION For complete information on Neuroendocrine Tumors Market Insights, Epidemiology & Market Forecast-2028 please click the link below CLICK HERE OR Write Us At  info@delveinsight.com • DelveInsight © 2019 | All rights reserved

  8. ABOUT DELVEINSIGHT VISION ABOUT MISSION DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for improving their performances to stay ahead of the competitors. To be the most trusted market research & business consulting firm in the world; and to continue enable the Pharma & Bio-Tech companies to achieve their goals with the best strategic insight and competitive solution. The vision also is inclusive of becoming a one-stop solution provider for the entire gamut of drug development process. To provide “insights across the value chain” and helping the organization to take a prudent business decision through the use and analysis of actionable market intelligence. The mission also is to provide the most effective result and efficient service with utmost client care for maintaining a long-term relationship with them. • DelveInsight © 2019 | All rights reserved

  9. SERVICE OFFERINGS BY DELVEINSIGHT OPPORTUNITY ASSESSMENT 1 5 FORECASTING 2 6 PIPELINE REPORT STORE COMPETITIVE ANALYSIS 3 7 CONSULTING MARKET INTELLIGENCE 4 8 PHARMDELVE • DelveInsight © 2019 | All rights reserved

  10. CONTACT US blog/delveInsight/ info@delveinsight.com +91-11-4568 9769 twitter/delveInsight LinkedIn/delveInsight www.delveinsight.com • DelveInsight © 2019 | All rights reserved

  11. THANK YOU

More Related